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Ab s t r a c t
Corticobasal degeneration (CBD) is a rare, progressive movement disorder characterized neuropathologically by wide-
spread neuronal and glial pathology including tau-immunoreactive neuronal cytoplasmic inclusions (NCI), oligoden-
droglial inclusions (GI), and astrocytic plaques (AP). However, β-amyloid (Aβ) deposits have been observed in the
cerebral cortex and/or hippocampus in some cases of CBD. To clarify the role of Aβ deposition in CBD, the densities
and spatial patterns of the Aβ deposits were studied in three cases. In two cases, expressing apolipoprotein E (APOE)
genotypes 2/3 or 3/3, the densities of the Aβ deposits were similar to those in normal elderly brain. In the remaining
case, expressing APOE genotype 3/4, Aβ deposition was observed throughout the cerebral cortex, sectors CA1 and
CA2 of the hippocampus, and the molecular layer of the dentate gyrus. The densities of the Aβ deposits in this case
were typical of those observed in Alzheimer’s disease (AD). In the three cases, clustering of Aβ deposits, with clusters
ranging in size from 200 to >6400 µm in diameter, was evident in 25/27 (93%) of analyses. In addition, the clusters
of Aβ deposits were regularly distributed parallel to the tissue boundary in 52% of analyses, a spatial pattern similar
to that observed in AD. These results suggest: (1) in some CBD cases, Aβ pathology is age-related, (2) more extensive
Aβ deposition is observed in some cases, the density and spatial patterns of the Aβ deposits being similar to AD, 
and (3) extensive deposition of Aβ in CBD may be associated with APOE allele ε4. 
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Corticobasal degeneration (CBD) is a rare, progre s-
sive movement disorder [29], the most characteris -
tic clinical features of which in clude limb dysfunction
[42,43,51], parkinsonism [49], apraxia [43], and de -
men tia [49]. An individual patient, however, may exhi -
bit a wide variety of clinical symptoms [46] including
myoclonus [23], memory loss, be ha viour al change,
speech, and gait problems [43]. 
Neuropathologically, CBD is characterized by
a pro gressive cortical atrophy affecting the anterior
ce rebral cortex [46], the fronto-parietal region [33],
and the superior temporal cortex [33]. As a conse-
quence, the disease is regarded as a subtype of fron-
totemporal lobar degeneration (FTLD) [22]. There is
atrophy of the basal ganglia, including the caudate
nucleus [39,47] and substantia nigra (Kawasaki et al.
1996). In addition, widespread neuronal and glial
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pathology is present including ballooned neurons
(BN) [41], neuropil threads [35], tau-immunoreactive
neuronal cytoplasmic inclusions (NCI) [33], oligoden-
droglial inclusions (GI) [40], and astrocytic plaques
(AP) [26]. CBD is therefore also classified as a tauopa-
thy, a group of disorders that includes Alzheimer’s
disease (AD), Pick’s disease (PiD), progressive
supranuclear palsy (PSP), the NFT-predominant form
of senile dementia (NFT-SD), argyrophilic grain dis-
ease (AGD), and the parkinsonism-dementia complex
of Guam (Guam PDC) [28].
During a quantitative study of the pathology of 
12 cases of CBD [17], β-amyloid (Aβ) deposits were
observed in the cerebral cortex and/or hippocampus
in three cases. Aβ deposits have been reported previ-
ously in CBD [43] and could represent the overlap or
co-occurrence of CBD with AD [10,18]. Hence, to clari-
fy the role of Aβ deposition in CBD, the density, distri-
bution, and spatial pattern of the Aβ deposits were
studied in these three cases and compared with pre-
viously reported data from normal elderly brains [2,3]
and from AD [2,11,15].
Material and methods
Cases
The CBD cases (Table I) were obtained from the
Brain Bank, Department of Neuropathology, Institute
of Psychiatry, King’s College London, UK. There is no
specific clinical phenotype of CBD as diverse presen-
tations of the disease are present [27]. However, the
pathology of the cases was consistent with the crite-
ria recommended by the National Institute of Health
(NIH) Office of Rare Diseases for the pathological diag-
nosis of CBD [27]. First, NCI, GI and AP were present.
Second, inclusions were present in the white and grey
matter of various cortical and striatal regions. Third,
neuronal loss was present in focal cortical areas and in
the substantia nigra. CBD can be confused with PSP
with cortical involvement and these two disorders
were separated by the absence of ‘tuft-shaped astro-
cytes’ [50] and the lower density of inclusions in the
subthalamic nucleus in CBD [48]. The apolipoprotein E
(APOE) genotype of two of the cases (A, B) was 2/3 or
3/3 while the genotype of the third case (C) was 3/4.
Tissue preparation
After death, the consent of the next of kin was
obtained for brain removal, following local Ethical
Committee procedure and the 1995 Declaration of
Helsinki (as modified Edinburgh, 2000). Tissue blocks
were taken from the frontal cortex at the level of the
genu of the corpus callosum to study the superior
frontal gyrus (SFG) and motor cortex (MC), parietal
cortex (PC) to study the superior parietal gyrus (SPG)
at the level of the splenium of the corpus callosum,
occipital cortex to study areas B17 and B18, and tem-
poral cortex at the level of the lateral geniculate body.
Within the temporal lobe, the superior temporal gyrus
(STG) (B22), parahippocampal gyrus (PHG) (B28), hip-
pocampus (HC), and dentate gyrus (DG) were investi-
gated. Sequential tissue sections were stained by the
following procedures: (1) haematoxylin and eosin
(H/E), (2) ubiquitin, (3) phosphorylation-independent
rabbit polyclonal antibody TP007 against tau [21], and
(4) rabbit polyclonal antibody raised against the 
12-28 amino acid sequence of the Aβ protein [45]. 
The three most common morphological subtypes of
Aβ depo sit were identified in the Aβ-immunolabelled
sections using previously defined criteria [6,24]: (1) dif-
 fuse deposits were 10-200 µm in diameter, irregular 
in shape with diffuse boundaries, and lightly stained,
(2) primitive deposits were 20-60 µm, well demarcated,
more symmetrical in shape, and strongly stained, 
(3) classic deposits were 20-100 µm, had a distinct cen-
tral ‘core’ surrounded by a ‘corona’ of dystrophic neu-
rites, and (4) compact deposits comprised a conden -
sed core of Aβ without the presence of a corona.
Case Gender Age Onset BW BS/CB Atrophy APOE
A F 55 44 1060 150 T 2/3
B F 68 – 1082 129 F, P 3/3
C F 69 65 1074 169 F, P, T 3/4
Table I. Demographic and gross brain features of the three corticobasal degeneration (CBD) cases studied
F – female, BW – total brain weight (gm), BS/CB – weight of brainstem and cerebellum (gm), T – temporal lobe, F – frontal lobe, P – parietal lobe, 
APOE – apolipoprotein E genotype
β-amyloid (Aβ) in corticobasal degeneration
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Morphometric methods 
In each cortical region, Aβ deposits were counted
along a strip of tissue using 1000 × 200 µm contigu-
ous sample fields, the short edge of the sample field
being aligned with the pia mater [8,12]. Contiguous
samples were located in the upper cortical laminae
and included lamina I, II, and most of III, the short
edge of the sample field being aligned with the sur-
face of the pia mater. In the hippocampus, the lesions
were counted from CA1 to CA4. From CA1 to CA3, the
short dimension of the contiguous sample field was
aligned with the alveus. Sampling was continued into
sector CA4 using a guideline marked on the slide. In
the DG, the sample field was aligned with the upper
edge of the granule cell layer since Aβ deposits were
present within the molecular layer.
Data analysis
The spatial pattern of the Aβ deposits in each brain
region was studied using spatial pattern analysis
described previously [1,5,9,12]. This method uses the
variance-mean ratio (V/M) of the data to determine
whether the Aβ deposits were distributed randomly
(V/M = 1), regularly (V/M < 1), or were clustered 
(V/M > 1) along a strip of tissue. Counts of deposits in
adjacent sample fields were added together succes-
sively to provide data for increasing field sizes, e.g.,
200 × 1000 µm, 400 × 1000 µm, 800 × 1000 µm etc.,
up to a size limited by the length of the strip sampled
and the V/M ratio calculated for each size. V/M was
then plotted against field size to determine whether
the clusters of a feature were regularly or randomly
distributed and to estimate the mean cluster size 
parallel to the tissue boundary. A V/M peak indicates
the presence of regularly spaced clusters while an in -
crease in V/M to an asymptotic level suggests the
presence of randomly distributed clusters. The statisti-
cal significance of a peak was tested using a 't' test [5].
Results
The three most common morphological types of
Aβ deposit commonly found in AD, viz., diffuse, pri m-
itive, and classic deposits, were also observed in 
the CBD cases (Fig. 1). In addition, a smaller number
of more ‘compact’ Aβ deposits were identified. Two
of the cases (A, C) had all four types of Aβ deposit
while case B had diffuse and classic-type deposits
only.
A
Fig. 1. β-amyloid (Aβ) deposits in a case of corti-
cobasal degeneration CBD. A) Diffuse deposit in
the frontal cortex, B) a primitive β-amyloid (Aβ)
deposit in the molecular layer of the dentate
gyrus, and C) a classic (cored) β-amyloid (Aβ)
deposit in the parahippocampal gyrus. Compact
deposits are very similar to cored deposits but
without the surrounding corona (polyclonal
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β-amyloid (Aβ) in corticobasal degeneration
The density of Aβ deposits in each brain region of
each case is shown in Table II. In two cases (A, B), the
density of the primitive, classic and compact Aβ
deposits was generally low (<1 deposit per mm2) and
their distribution was restricted to either the frontal
and motor cortex (case A) or to the occipital cortex
(case B). Of these cases, case A had greater numbers
of diffuse deposits in the frontal and motor cortex. In
one case (case C), there was a greater density of Aβ
deposits throughout the cerebral cortex and deposits
were also present in the CA sectors of the hippocam-
pus and molecular layer of the DG. In case C, the den-
sity of the diffuse deposits was greatest in the occip-
ital and temporal cortex (16-18 deposits per mm2),
primitive deposits in the temporal cortex (14 deposits
per mm2), classic deposits in the frontal cortex 
(5.3 deposits per mm2), and compact deposits in the
parietal cortex (2.65 deposits per mm2).
The spatial pattern of the Aβ deposits in each
brain region is shown in Table III. Clustering of the Aβ
deposits, with clusters ranging in size from 200 to
>6400 µm in diameter, was evident in 25/27 (93%) of
the brain areas analysed. In addition, clusters of Aβ
deposits were regularly distributed parallel to the tis-
sue boundary in 52% of the brain areas exhibiting
clustering. In two cortical areas of case C, there was
evidence of clustering at two scales, suggesting that
the smaller clusters were aggregated into larger clus-
ters. In the remaining analyses, large clusters of Aβ
deposits were observed, of at least 6400 µm in diame -
ter, but without evidence of regular spacing.
Discussion
Of the original 12 cases of CBD studied using
quantitative methods [17], Aβ deposition was
observed in three of the cases. In two cases, the den-
sity of the Aβ deposits was low and their distribution
was restricted to a small number of cortical regions.
The density of the Aβ deposit subtypes in these two
cases was within the range reported for elderly non-
demented brains [2,3]. Aβ pathology in the remaining
CBD case, however, was more extensive and showed
similarities to that previously reported in AD [2,13,15].
The densities of Aβ deposits in the frontal, occipital
and temporal cortex were similar to AD [2-4] but the
density in the parietal cortex was significantly lower
than in AD. In addition, the spatial pattern of the Aβ
deposits, i.e., clustering of deposits with a regular dis-
tribution of clusters parallel to the tissue boundary,
was similar to that reported in AD [1,7,11]. 
A number of hypotheses could account for Aβ de -
position in CBD. First, the presence of Aβ deposits could
be age-related. The density and distribution of Aβ de -
posits in two of the CBD cases is similar to normal con-
Aβ deposit subtypes
Case Region Diffuse Primitive Classic Compact
A SFC 5.00 0.10 0.35 0.85
MC 3.40 0.10 1.10 0.50
B OC 0.13 0 0.10 0
C SFC 3.06 4.55 5.30 0.55
PC 0.10 0.25 0.80 2.65
OC 16.45 4.40 1.50 0
LOT 17.60 13.60 1.55 0
PHG 16.10 11.05 1.45 0.10
CA1/4 1.95 0.45 0.25 0.05
DG 0.40 2.20 0 0
Table II. Densities of the β-amyloid (Aβ) deposit subtypes (per mm2) in brain regions where Aβ deposits
were present in three cases of corticobasal degeneration (CBD)
SFC – frontal cortex, MC – motor cortex, PC – parietal cortex, OC – occipital cortex, LOT – lateral occipitotemporal gyrus, PHG – parahippocampal gyrus, 
CA1/4 – hippocampus sectors CA1 to 4, DG – dentate gyrus
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trol brains [2,3], consistent with aging. A number of
studies of Aβ pathology have demonstrated overlaps
between AD and aging. Mann and Jones [38], for exam-
ple, observed Aβ deposits in non-demented individuals
older than 60 years, deposits being rare before this age.
After 60 years of age, Aβ deposits were present in
a variety of different disorders due to aging, especially
in the temporal cortex [37]. In 14 non-demented elder-
ly cases [3], Aβ deposits were present in the temporal
lobe in eight cases, but only in cortical gyri, the CA sec-
tors of the HC and DG being spared. In addition, there
were variations in the density of Aβ deposits in control
cases with a significant overlap with AD. The pattern of
clustering of the Aβ deposits was also similar in control
and AD cases, i.e., the deposits were aggregated into
clusters that were regularly distributed parallel to the
pia mater, suggesting that the formation of Aβ
deposits was similar in AD and in aging [3]. In a further
study of non-demented centenarians [25], Aβ deposits
were recorded in the PHG, whether demented or not
demented, but the hippocampus was spared, suggest-
ing little relationship between lesion density and sever-
ity of mental deficits. 
Secondly, in case C the density and distribution of
the deposits were similar to those reported in AD [2,3]
and therefore Aβ deposition in this case may be the
result of the co-existence of AD and CBD [10,11,18].
The clinical syndrome of CBD is complex and variable
and at least 50% of patients exhibit the signs and
symptoms of an additional disorder, e.g., AD, PSP, or
Parkinson’s disease (PD) [43]. Typical AD cases, how-
ever, also have abundant neurofibrillary tangles (NFT).
The paired helical filaments (PHF) of the inclusions
present in CBD are wider than those of AD and have
a longer periodicity [36]. In addition, PHF-tau in CBD is
composed predominantly of 4-repeat (4R) tau [44]
while abnormally aggregated tau from AD contains
both 3R and 4R tau [30]. Hence, although the Aβ
pathology in the present case resembles that of AD,
there are differences in tau-immunoreactive patholo-
gy compared with AD. 
Third, Aβ deposits in CBD could be associated
with the development of capillary amyloid angiopathy
(CAA), which often results in increased Aβ deposition
[14]. The deposition of Aβ in capillary and arteriolar
walls is a common pathological observation in AD
and in unselected post-mortems with age [19]. There
was no evidence in the present cases, however, of 
any significant Aβ deposition in relation to the vessel
walls.
Aβ deposit subtypes
Case Region Diffuse Primitive Classic Compact
A SFC >3200 – 200 >3200
MC >3200 – 800 200
B OC R – – –
C SFC >6400 400 200, 1600 >6400
PC – R 800 >3200
OC 3200 200, 800 800 –
LOT >6400 >6400 >6400 –
PHG >6400 1600 >6400 –
CA1/4 >6400 200 200 –
DG – 1600 – –
Table III. Spatial patterns of β-amyloid (Aβ) deposit subtypes in various brain regions in three cases
of corticobasal degeneration (CBD)
Data are the dimensions in µm of clusters of Aβ deposits measured parallel to the tissue boundary. >3200 etc represent the minimum size of large clusters
without regular spacing. Remaining data represent the dimension of regularly distributed clusters. Where there are two figures, small clusters are aggregated
into larger ‘superclusters’. R = random distribution of deposits. 
FC – frontal cortex, PC – parietal cortex, MC – motor cortex, OC – occipital cortex, LOT – lateral occipitotemporal gyrus, PHG – parahippocampal gyrus, 
CA1/4 – hippocampus sectors CA1 to 4, DG – dentate gyrus
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Fourth, Aβ deposition is also related to APOE
genotype, enhanced deposition being observed in
cases expressing the ε4 allele [20]. An increased 
frequency of allele ε4 has been recorded in cases of
CBD, and in 5/7 patients expressing the ε4 allele,
Aβ deposition was recorded in the hippocampus
and cerebral cortex [43]. In the present study, case C
had the highest densities and most widespread 
distribution of Aβ deposits and expressed genotype
3/4 whereas the other two cases with low densities
of deposits expressed either genotype 2/3 or 3/3.
Hence, it is hypothesized that enhanced Aβ deposi-
tion in case C represents the influence of APOE
allele ε4.
In conclusion, in a quantitative study of 12 cases
of CBD, three were shown to possess AD-type patho -
logy in the form of Aβ deposits. The density of Aβ
deposits in two of the cases was similar to that of 
elderly non-demented brains but in one case, the
den sity and spatial patterns of the deposits resem-
bled those of AD. Aβ pathology has now been shown
to be associated with dementia with Lewy bodies
(DLB) [16], amyotrophic lateral sclerosis (ALS) [31],
Creutzfeldt-Jakob disease (CJD) [31], as well as CBD
[43]. Hence, Aβ pathology can be observed in several
distinct clinical contexts and it is possible that pre -
sence of the APOE ε4 allele is the common feature in
these disorders enhancing Aβ deposition.
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